| Free radicals, metals and antioxidants in oxidative stress-induced cancer M Valko, CJB Rhodes, J Moncol, MM Izakovic, M Mazur Chemico-biological interactions 160 (1), 1-40, 2006 | 9315 | 2006 |
| Pembrolizumab for the treatment of non–small-cell lung cancer EB Garon, NA Rizvi, R Hui, N Leighl, AS Balmanoukian, JP Eder, ... New England Journal of Medicine 372 (21), 2018-2028, 2015 | 6385 | 2015 |
| Chimeric antigen receptor T cells for sustained remissions in leukemia SL Maude, N Frey, PA Shaw, R Aplenc, DM Barrett, NJ Bunin, A Chew, ... New England Journal of Medicine 371 (16), 1507-1517, 2014 | 5704 | 2014 |
| Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice … AC Wolff, MEH Hammond, DG Hicks, M Dowsett, LM McShane, ... Journal of clinical oncology 31 (31), 3997-4013, 2013 | 5347 | 2013 |
| 4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4) F Cardoso, E Senkus, A Costa, E Papadopoulos, M Aapro, F André, ... Annals of Oncology 29 (8), 1634-1657, 2018 | 1228 | 2018 |
| 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) F Cardoso, S Paluch-Shimon, E Senkus, G Curigliano, MS Aapro, F André, ... Annals of Oncology 31 (12), 1623-1649, 2020 | 1028 | 2020 |
| Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy A Sistigu, T Yamazaki, E Vacchelli, K Chaba, DP Enot, J Adam, I Vitale, ... Nature medicine 20 (11), 1301-1309, 2014 | 1022 | 2014 |
| Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice … LN Harris, N Ismaila, LM McShane, DF Hayes Journal of oncology practice 12 (4), 384-389, 2016 | 990 | 2016 |
| ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a … C Luchini, F Bibeau, MJL Ligtenberg, N Singh, A Nottegar, T Bosse, ... Annals of Oncology 30 (8), 1232-1243, 2019 | 783 | 2019 |
| Antibody therapeutics in cancer MX Sliwkowski, I Mellman Science 341 (6151), 1192-1198, 2013 | 697 | 2013 |
| Advances and challenges in targeting FGFR signalling in cancer IS Babina, NC Turner Nature Reviews Cancer 17 (5), 318-332, 2017 | 665 | 2017 |
| Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study MV Dieci, C Criscitiello, A Goubar, G Viale, P Conte, V Guarneri, G Ficarra, ... Annals of oncology 25 (3), 611-618, 2014 | 537 | 2014 |
| Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association … E De Azambuja, AP Holmes, M Piccart-Gebhart, E Holmes, S Di Cosimo, ... The lancet oncology 15 (10), 1137-1146, 2014 | 519 | 2014 |
| Targeting FGFR signaling in cancer M Touat, E Ileana, S Postel-Vinay, F André, JC Soria Clinical cancer research 21 (12), 2684-2694, 2015 | 514 | 2015 |
| The two faces of reactive oxygen species in cancer CR Reczek, NS Chandel Annual review of cancer biology 1, 79-98, 2017 | 493 | 2017 |
| Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology Clinical Practice Guideline C Van Poznak, MR Somerfield, RC Bast, M Cristofanilli, MP Goetz, ... Journal of clinical oncology 33 (24), 2695, 2015 | 429 | 2015 |
| Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer F André, T Bachelot, M Campone, F Dalenc, JM Perez-Garcia, SA Hurvitz, ... Clinical cancer research 19 (13), 3693-3702, 2013 | 345 | 2013 |
| Two faces of vitamin C—antioxidative and pro-oxidative agent J Kaźmierczak-Barańska, K Boguszewska, A Adamus-Grabicka, ... Nutrients 12 (5), 1501, 2020 | 240 | 2020 |
| Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial Y Cheng, L Han, L Wu, J Chen, H Sun, G Wen, Y Ji, M Dvorkin, J Shi, ... Jama 328 (12), 1223-1232, 2022 | 137 | 2022 |
| Preclinical activity of ARQ 087, a novel inhibitor targeting FGFR dysregulation TG Hall, Y Yu, S Eathiraj, Y Wang, RE Savage, JM Lapierre, B Schwartz, ... PLoS One 11 (9), e0162594, 2016 | 135 | 2016 |
Gaiane SimoniaTbilisi State Medical University, GeorgiaVerified email at tsmu.edu
